Top 30 fund performance in the first half of the year | 90% of heavy pharmaceutical stocks

Pharmaceutical Network July 3rd, with the end of the first half of the year, the performance of public funds also surfaced. In the first half of the year, the stock market was adjusted sharply, more than 10 industry indices fell more than 20%, and the overall performance of public funds was not good. Statistics In the first half of the year, stock funds fell by an average of nearly 12%, and mixed funds fell by an average of nearly 5%. It is worth noting that pharmaceutical-themed funds are eye-catching, among the top 30 active managed funds. There are 27 funds in heavy pharmaceutical stocks.

From the overall performance of public funds, Wind information statistics show that in the first half of this year, stock funds fell by 11.89% on average; mixed funds fell by an average of 4.73%; bond funds rose by an average of 1.52%, money market funds rose by an average of 1.98%, QDII funds ( As of June 28) the average increase was 0.50%.

Specifically, of the 2,524 active management funds that were established before 2018, only 577 had positive returns, of which only 100 had a yield of more than 5%, and 40 had a yield of more than 10%. There were 2,029 funds that fell in half a year, of which 1,375 were more than 5%, accounting for more than 50%; as many as 749, more than 10%, and 55 were more than 20%.

From the end-to-end performance of active management funds, Fuguo Precision Medical, China Europe Medical health C and Fuguo New Power A ranked in the top three. In the first half of the year, they have returned 29.52%, 24.09% and 23.85% respectively. The last three declines were 32.07%, 31.09% and 27.9% respectively. The difference between the first and last performances was 61.59%.

Among the top funds, the medical theme fund led the first half of the public fund performance list. The top 30 in the list, in addition to Bank of Communications Alpha, Bank of Communications advantage industry, Noel Lee, China Post enjoys a regular year and rich new country Except for Power A and Fuguo New Power C, the rest of the funds are all medical theme funds. It is worth mentioning that Fuguo New Power A, Fuguo New Power C and Noel Lixin are all full warehouse pharmaceutical stocks. That is, in the first half of the year Among the top 30 active management funds, 27 funds have heavy positions in pharmaceutical stocks.

In the weak market in the first half of this year, although the Shenwan Pharmaceutical Biological Index rose by only 3.11%, the leading stocks were eye-catching, Hengrui Medicine, East China Medicine, Pien Tze Huang, Zhifei Bio, Kangtai Bio, Changchun High-tech, Tonghua The stock price of Dongbao and other stocks reached a new high. In the market situation of 'leading for the United States', it contributed a lot of benefits to the public fund.

In the first half of this year, the overall market fell. In the 28 Shenwan-level industries, there are only leisure services. medicine Biological and food and beverages rose, with 20 industries falling by more than 15%. Among them, 11 sectors of communications, electrical equipment, machinery and equipment, non-ferrous metals, architectural decoration, electronics and so on fell more than 20%. Relatively speaking, public fund performance outperformed mainly Market index.

The Galaxy Securities Fund Research Center believes that the public fund will resist the market's sharp adjustment in the first half of this year by embracing the deterministic and stable pharmaceutical bio, food and beverage and household appliances sectors. The overall decline is significantly better than the average market decline.

From the perspective of fund managers, the rich country fund Yuyang became the biggest winner in the first half of the year. According to public data, Yu Yang has served as a pharmaceutical industry analyst in First Securities, Huachuang Securities and Essence Securities since August 2011, and joined in November 2015. Wells Fargo Fund, November 25, 2017, is the manager of Fuguo New Power Fund. On November 17, 2017, he served as the manager of Fuguo Precision Medical Fund. On February 8, 2018, he served as Fuguo Medical. health care The industry fund manager, all the funds managed by the above-mentioned funds, all of them have heavy pharmaceutical stocks, and their returns in the first half of the year exceeded 21%. From the more than half a year since their fund managers, they have seized the accelerated rise of pharmaceutical leading stocks.

Bank of Communications fund manager He Shuai’s performance is eye-catching. The Bank of Communications’ Alpha Fund’s return for the first half of the year was 14.97%, and the Bank of Communications’s industry fund return was 14.59%. The Bank of Communications’ continued growth theme fund was established on January 12 this year. Since its establishment, the return has been 9.13%. The data shows that He Shuai has been the Banking Advantage Industry Fund Manager since July 9, 2015, and has served as the Bank of Communications Alpha Fund Manager since September 16, 2015, in any year under his management. According to the fund's 2018 quarterly report, among the top ten Awkwardness stocks of the funds it manages, there are no pharmaceutical stocks in the first half of the year, such as Maya Bank, Meiya Optoelectronics, New Classic, and China Testing. .